Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is an Ontario-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and the understanding of psilocybin use and consumer experiences.

In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.

Following the acquisition of Filament Health Corp., Red Light Holland is expanding its capabilities in natural psilocybin drug development, supporting clinical research collaborations with leading academic and medical institutions through the supply of Filament’s botanical psilocybin drug candidate, PEX010.

Red Light Holland’s management and advisory team brings together expertise across pharmaceutical development, clinical research, regulatory compliance, cultivation, and commercialization.

Red Light Holland ‘s management and advisory members are comprised of a core group of highly skilled individuals with the wealth of combined knowledge and experience (relating to growing, mass-producing, compliance, distributing, marketing and managing, etc.) necessary to help fix Red Light Holland as a leader in this early-stage, emerging field.